Home Daily Stock Opinions and Ratings Theragenics Corp (TGX-N)

Trending stocks today

Royalty Pharma plc Comcast Corp Onity Group. Inc. Allstate CVS Health Corp Savaria Corp Jamieson Wellness Stella-Jones Inc. Tesla Inc CVS Health Corp Advanced Micro Devices Broadcom Mastercard Inc. Superior Plus Corp Omnicom Group GlaxoSmithKline PLC Leidos Holdings, Inc. Africa Oil Corp. International Petroleum Company Ecora Resources

Theragenics Corp (TGX-N)

NEW AI Investor Insights
2 watching

0.00
0.00 (0.00%) 1d
0
PAST TOP PICK

Theragenics Corp(TGX-N)

06/12/2011
Theragenics Corp
(Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt.
biotechnology / pharmaceutical
Benj Gallander
$1.660
No
UnlockRating
PAST TOP PICK

Theragenics Corp(TGX-N)

03/11/2011
Theragenics Corp
(A Top Pick Nov 11/10. Up 28.57%.)
biotechnology / pharmaceutical
Benj Gallander
$1.600
Owned
UnlockRating
PAST TOP PICK

Theragenics Corp(TGX-N)

04/10/2011
Theragenics Corp
(Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list.
biotechnology / pharmaceutical
Benj Gallander
$1.250
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

11/11/2010
Theragenics Corp
Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet.
biotechnology / pharmaceutical
Benj Gallander
$1.300
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

24/12/2007
Theragenics Corp
Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet.
biotechnology / pharmaceutical
Benj Gallander
$3.710
Owned
UnlockRating
WEAK BUY

Theragenics Corp(TGX-N)

06/10/2006
Theragenics Corp
Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management.
biotechnology / pharmaceutical
Benj Gallander
$3.070
Owned
UnlockRating
PAST TOP PICK

Theragenics Corp(TGX-N)

30/01/2006
Theragenics Corp
(A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list.
biotechnology / pharmaceutical
Benj Gallander
$3.480
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

06/09/2005
Theragenics Corp
In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field.
biotechnology / pharmaceutical
Ben Stadelmann
$3.150
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

12/01/2005
Theragenics Corp
They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.
biotechnology / pharmaceutical
Ben Stadelmann
$3.970
Owned
UnlockRating
PAST TOP PICK

Theragenics Corp(TGX-N)

09/11/2004
Theragenics Corp
(A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management.
biotechnology / pharmaceutical
Benj Gallander
$3.900
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

16/09/2004
Theragenics Corp
A demographics play in treatment of prostrate cancer. Dominant in their field. Midicare payment problem seems to be getting worked out. R&D is looking for other cancer treatments.
biotechnology / pharmaceutical
Ben Stadelmann
$3.740
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

21/07/2004
Theragenics Corp
biotechnology / pharmaceutical
Benj Gallander
$4.360
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

16/07/2004
Theragenics Corp
Had revenues over $50 million and stock price was over $30. Revenues then dropped to $30 million. Prostate cancer continues to grow demographically and they have a proven product for this. A lot of competition. No long-term debt.
biotechnology / pharmaceutical
Benj Gallander
$4.370
Owned
UnlockRating
Showing 1 to 13 of 13 entries
  • «
  • ‹
  • 1
  • ›
  • »

Theragenics Corp(TGX-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Theragenics Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Theragenics Corp(TGX-N) Frequently Asked Questions

What is Theragenics Corp stock symbol?

Theragenics Corp is a OTC stock, trading under the symbol TGX-N on the (). It is usually referred to as or TGX-N

Is Theragenics Corp a buy or a sell?

In the last year, there was no coverage of Theragenics Corp published on Stockchase.

Is Theragenics Corp a good investment or a top pick?

Theragenics Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Theragenics Corp.

Why is Theragenics Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Theragenics Corp worth watching?

In the last year, there was no coverage of Theragenics Corp published on Stockchase.

What is Theragenics Corp stock price?

On , Theragenics Corp (TGX-N) stock closed at a price of $.

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Get Access To Watchlist

Latest Buy Signals

GSY-Tgoeasy
goeasy
$161.86
0.20 (0.12%)
LHX-NL3Harris Technologies
L3Harris Technologies
$223.12
-1.23 (-0.55%)
MGA-TMega Uranium
Mega Uranium
$0.35
0.00 (0.00%)
DC.A-TDundee Corp. (A)
Dundee Corp. (A)
$1.59
0.01 (0.63%)
SGD-XSnowline Gold
Snowline Gold
$5.11
0.02 (0.39%)
Advertising

Today's Top Picks

ECOR-TEcora Resources
Ecora Resources
$1.31
0.13 (9.03%)
IPCO-TInternational Petroleum Company
International Petroleum Company
$16.05
0.21 (1.29%)
AOI-TAfrica Oil Corp.
Africa Oil Corp.
$1.94
0.04 (2.02%)
LDOS-NLeidos Holdings, Inc.
Leidos Holdings, Inc.
$153.16
0.18 (0.12%)
GSK-NGlaxoSmithKline PLC
GlaxoSmithKline PLC
$33.95
-0.22 (-0.65%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

III-TImperial Metals Corp
Imperial Metals Corp
$1.93
-0.07 (-3.76%)
IMG-TIamgold Corp
Iamgold Corp
$7.60
-0.31 (-4.25%)
PPTA-QPerpetua Resources
Perpetua Resources
$11.91
0.10 (0.83%)
DG-NDollar General Corp.
Dollar General Corp.
$76.94
-1.48 (-1.96%)
VRT-NVertiv Holdings
Vertiv Holdings
$125.78
0.74 (0.58%)

Most Recent Experts

Rule

Rick Rule

Rule Investment Medial

Stockchase

Stockchase Insights

5i Research

Pyle

Andrew Pyle

The Pyle Group, Scotia Wealth Mgt.

Panic-Proof (Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Buzzing

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.